StrePTococcus pneumoniae infection: A Canadian perspective

Expert Review of Anti-Infective Therapy

Volumn 11, Issue 8, 2013, Pages 781-791

  Deng, Xianding ^a,b   Church, Deirdre ^c,d   Vanderkooi, Otto G ^c,d,e   Low, Donald E ^a,b   Pillai, Dylan R ^c,d  

^a PUBLIC HEALTH ONTARIO   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d CALGARY LABORATORY SERVICES   (Canada)

^e ALBERTA CHILDREN'S HOSPITAL   (Canada)

Author keywords

invasive pneumococcal diseases (IPD); non vaccine serotypes; pneumococcal conjugate vaccines (PCVs); pneumococcal outbreaks; protein vaccine; serotype replacement disease; StrePTococcus pneumoniae; vaccine serotypes

Indexed keywords

MACROLIDE; PENICILLIN DERIVATIVE; PNEUMOCOCCUS VACCINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ACUTE OTITIS MEDIA; ANTIBIOTIC RESISTANCE; BACTERIAL COLONIZATION; BACTERIAL PNEUMONIA; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; BACTERIUM ISOLATE; CANADA; COMMENSAL; DISEASE SURVEILLANCE; DRUG DEVELOPMENT; DRUG EFFECT; DRUG EFFICACY; EPIDEMIC; HEALTH IMPACT ASSESSMENT; HUMAN; INCIDENCE; INFECTION CONTROL; NASOPHARYNX; PNEUMOCOCCAL INFECTION; PUBLIC HEALTH; REVIEW; SEROTYPE; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

CANADA; DISEASE OUTBREAKS; DRUG RESISTANCE, BACTERIAL; HUMANS; INCIDENCE; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; SEROTYPING; STREPTOCOCCUS PNEUMONIAE;

EID: 84887584901     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.2013.814831     Document Type: Review

References (132)

1. Ausina V, Coll P, Sambeat M et al. Prospective study on the etiology of community-Acquired pneumonia in children and adults in Spain. Eur. J. Clin. Microbiol. Infect. Dis. 7(3), 342-347 (1988
2. Arditi M, Mason EO Jr, Bradley JS et al. Three-year multicenter surveillance of pneumococcal meningitis in children: Clinical characteristics, and outcome related to penicillin suscePTibility and dexamethasone use. Pediatrics 102(5), 1087-1097 (1998
3. Bluestone CS, Martin L. Ten-year review of otitis media pathogens. Pediatr. Infect. Dis. J. 11(Suppl.), 7-11 (1992
4. O'Brien KL, Millar EV, Zell ER, Bronsdon M et al. Effect of pneumococcal conjugate vaccine on nasopharyngeal colonization among immunized and unimmunized children in a community-randomized trial. J. Infect. Dis. 196(8), 1211-1220 (2007
5. De Wals P, Robin E, Fortin E et al. Pneumonia after implementation of the pneumococcal conjugate vaccine program in the province of Quebec, Canada. Pediatr. Infect. Dis. J. 27(11), 963-968 (2008
6. Wals PD, Carbon M, Sévin E et al. Reduced physician claims for otitis media after implementation of pneumococcal conjugate vaccine program in the province of Quebec, Canada. Pediatr. Infect. Dis. J. 28(9), 271-275 (2009)
7. Grijalva CG, Nuorti JP, Arbogast PG et al. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: A time-series analysis. Lancet 369(9568), 1179-1186 (2007
8. Poehling KA, Szilagyi PG, Grijalva CG et al. Reduction of frequent otitis media and pressure-equalizing tube insertions in children after introduction of pneumococcal conjugate vaccine. Pediatrics 119, 707-715 (2007
9. Scheifele D, Halperin S, Pelletier L. Invasive pneumococcal infections in Canadian children, 1991-1998: Implications for new vaccination strategies. Clin. Infect. Dis. 31, 58-64 (2000
10. Robinson KA, Baughman W, Rothrock G et al. Epidemiology of invasive StrePTococcus pneumoniae infections in the United States, 1995-1998: Opportunities for prevention in the conjugate vaccine era. JAMA 285(13), 1729-1735 (2001
11. Kellner JD, Vanderkooi OG, MacDonald J et al. Changing epidemiology of invasive pneumococcal disease in Canada, 1998-2007: Update from the Calgary-Area StrePTococcus pneumoniae research (CASPER) study. Clin. Infect. Dis. 49(2), 205-212 (2009)
12. Munoz-Almagro C, Jordan I, Gene A et al. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine. Clin. Infect. Dis. 46, 174-182 (2008
13. Pai R, Moore MR, Pilishvili T et al. Postvaccine genetic structure of StrePTococcus pneumoniae serotype 19A from children in the United States. J. Infect. Dis. 192(11), 1988-1995 (2005
14. Bettinger JA, Scheifele DW, Kellner JD, Halperin SA et al. The effect of routine vaccination on invasive pneumococcal infections in Canadian children, Immunization Monitoring Program, Active 2000-2007. Vaccine 28, 2130-2136 (2010
15. Isaacman DJ, Mcintosh ED, Reinert RR. Burden of invasive pneumococcal disease and serotype distribution among StrePTococcus pneumoniae isolates in young children in Europe: Impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines. Int. J. Infect. Dis. 14(3), 197-209 (2010
16. Brueggeman A, Pai R, Crook DW, Beall B. Vaccine escape recombination emerge after pneumococcal vaccination in the United States. PLos Pathog. 3, 1628-1636 (2007
17. Desai S, McGeer A, Quach Thanh C, Elliott D. Update on the use of conjugate pneumococcal vaccines in childhood. Can. Commun. Dis. Rep. 36(ACS-12), 1-21 (2010
18. Bernatoniene J, Finn A. Advances in pneumococcal vaccines: Advantages for infants and children. Drugs 65(2), 229-255 (2005
19. Bogaert D, Hermans PW, Adrian PV, Rümke HC, De Groot R. Pneumococcal vaccines: An update on current strategies. Vaccine 22(17), 2209-2220 (2004
20. Rodgers GL, Klugman KP. The future of pneumococcal disease prevention. Vaccine 29(Suppl. 3), 43-48 (2011
21. Henrichsen J. Six newly recognized types of StrePTococcus pneumoniae. J. Clin. Microbiol. 33, 2759-2762 (1995
22. Feikin DR, Klugman KP. Historical changes in pneumococcal serogroup distribution: Implications for the era of pneumococcal conjugate vaccines. Clin. Infect. Dis. 35(5), 547-555 (2002
23. Hodges RG, Macleod CM. Epidemic pneumococcal pneumonia. V. Final considerations of the factors underlying the epidemic. Am. J. Hyg. 44, 237-243 (1946
24. Smillie W, Warnock G, White H. Study of a type I pneumococcus epidemic at the State Hospital at Worcester, Massachusetts. Am. J. Public Health 28, 293-298 (1938
25. Dixon JMS, Lipinski AE. Pneumococcal serotypes causing bacteremia and meningitis: Relevance to composition of pneumococcal vaccine. Can. Med. Assoc. J. 125, 263-267 (1981
26. Lamothe F, Delage G, Laverditre M, Saint-Antoine P. Serogroups and serotypes of pneumococci in Montreal: Correlates with age, outcome and indications for vaccinations. Can. Med. Assoc. J. 130, 737-740 (1984
27. Jette LP, Lamothe F. Surveillance of invasive StrePTococcus pneumonia infection in Quebec, Canada from 1984 to 1986: Serotype distribution, antimicrobial suscePTibility and clinical characteristics. J. Clin. Microbiol. 27(1), 1-5 (1989
28. Klugman KP. Pneumococcal resistance to antibiotics. Clin. Microbiol. Rev. 3, 171-196 (1990
29. Joffe MD, Alpern ER. Occult pneumococcal bacteremia: A review. Pediatr. Emer. Care 26, 48-457 (2010
30. Bettinger JA, Scheifele DW, Halperin SA et al. Invasive pneumococcal infections in Canadian children, 1998-2003: Implications for new vaccination programs. Can. J. Public Health 98, 111-115 (2007
31. Tyrrell GJ, Lovgren M, Chui N et al. Serotypes and antimicrobial suscePTibilities of invasive StrePTococcus pneumoniae pre-And post-seven valent pneumococcal conjugate vaccine introduction in Alberta, Canada, 2000-2006. Vaccine 27, 3553-3560 (2009
32. Winters M, Patrick DM, Marra F, Buxton J. Epidemiology of invasive pneumococcal disease in BC during the introduction of conjugated pneumococcal vaccine. Can. J. Public Health 99(1), 57-61 (2008
33. Demczuk WHB, Martin I, Griffith A et al. Serotype distribution of invasive StrePTococcus pneumoniae in Canada during the introduction of the 13-valent pneumococcal conjugate vaccine, 2010. Can. J. Microbiol. 58(8), 1008-1017 (2012
34. Deceuninck G, De Wals P, Boulianne N, De Serres G. Effectiveness of pneumococcal conjugate vaccine using a 2+1 infant schedule in Quebec, Canada. Pediatr. Infect. Dis. J. 29(6), 546-549 (2010
35. Sahni V, Naus M, Hoang L et al. The epidemiology of IPD in British Columbia following implementation of an infant immunization program: Increases in herd immunity and replacement disease. Can. J. Public Health 103(1), 29-33 (2012
36. Degani N, Navarro C, Deeks SL, Lovgren M. Invasive bacterial diseases in Northern Canada. Emerg. Infect. Dis. 14(1), 34-40 (2008
37. Plevneshi A, Svoboda T, Armstrong I et al. Population-based surveillance for invasive pneumococcal disease in homeless adults in Toronto. PLoS One 4(9), e7255 (2009
38. Hennessy TW, Singleton RJ, Bulkow LR et al. Impact of hePTavalent pneumococcal conjugate vaccine on invasive disease, antimicrobial resistance and colonization in Alaska Natives: Progress towards elimination of a health disparity. Vaccine 23, 5464-5473 (2005
39. Hsu K, Pelton S, Karumuri S et al. Massachusetts DePTment of Public Health Epidemiologists. Population-based surveillance for childhood invasive pneumococcal disease in the era of conjugate vaccine. Pediatr. Infect. Dis. J. 24, 17-23 (2005
40. Hicks LA, Harrison LH, Flannery B et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J. Infect. Dis. 196, 1346-1354 (2007
41. Williams BG. Estimates of worldwide distribution of child deaths from acute respiratory tract infections. Lancet Infect. Dis. 2, 25-32 (2002
42. Obaro SK, Madhi SA. Bacterial pneumonia vaccines and childhood pneumonia: Are we winning, refining, or redefining? Lancet Infect. Dis. 6, 150-161 (2006
43. Simonsen L, Taylor RJ, Young-Xu Y, Haber M, May L, Klugman KP. Impact of pneumococcal conjugate vaccination of infants on pneumonia and influenza hospitalization and mortality in all age groups in the United States. MBio. 2(1), e00309-10 (2011
44. Dubé E, De Wals P, Gilca V et al. Burden of acute otitis media on Canadian families. Can. Fam. Physician 57, 60-65 (2011
45. Morrow A, De Wals P, Petit G, Guay M, Erickson LJ. The burden of pneumococcal disease in the Canadian population before routine use of the seven-valent pneumococcal conjugate vaccine. Can. J. Infect. Dis. Med. Microbiol. 18(2), 121-127 (2007
46. Bluestone CD, Stephenson JS, Martin LM. Ten-year review of otitis media pathogens. Pediatr. Infect. Dis. J. 11(Suppl. 8), S7-S11 (1992
47. Black S, Shinefield H, Fireman B et al. Efficacy, safety and immunogenicity of hePTavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr. Infect. Dis. J. 19, 187-195 (2000
48. Fireman B, Black SB, Shinefield HR, Lee J, Lewis E, Ray P. Impact of the pneumococcal conjugate vaccine on otitis media. Pediatr. Infect. Dis. J. 22, 10-16 (2003
49. Brunton S, Pichichero ME. Acute otitis media: Influence of the PCV-7 vaccine on changes in the disease and its management. J. Fam. Practice 54, 11-16 (2005
50. Vayalumkal J, Kellner JD. Tympanocentesis for the management of acute otitis media in children: A survey of Canadian pediatricians and family physicians. Arch. Pediatr. Adolesc. Med. 158(10), 962-965 (2004
51. De Wals P, Lefebvre B, Defay F, Deceuninck G, Boulianne N. Invasive pneumococcal diseases in birth cohorts vaccinated with PCV-7 and/or PHiD-CV in the province of Quebec, Canada. Vaccine 30, 6416-6420 (2012
52. Earnshaw SR, McDade CL et al. Costeffectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada. BMC Infect. Dis. 12, 101 (2012
53. Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine. Vaccine 29(49), 9127-9131 (2011
54. Kaplan SL, Barson WJ, Lin PL et al. Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine. Pediatr. Infect. Dis. J. 32(3), 203-207 (2013
55. Hortal M, Estevan M, Laurani H, Iraola I, Meny M, Paysandú/Salto Study Group. Hospitalized children with pneumonia in Uruguay: Pre and post introduction of 7 and 13-valent pneumococcal conjugated vaccines into the National Immunization Program. Vaccine 30(33), 4934-4938 (2012
56. Cohen R, Levy C, Bingen E et al. Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal nasopharyngeal carriage in children with acute otitis media. Pediatr. Infect. Dis. J. 31(3), 297-301 (2012
57. Kellner JD, Scheifele D, Vanderkooi OG et al. Effects of routine infant vaccination with the 7-valent pneumococcal conjugate vaccine on nasopharyngeal colonization with StrePTococcus pneumoniae in children in Calgary, Canada. Pediatr. Infect. Dis. J. 27(6), 526-532 (2008
58. O'Brien KL, Millar EV, Zell ER Bronsdon M et al. Effect of pneumococcal conjugate vaccine on nasopharyngeal colonization among immunized and unimmunized children in a community-randomized trial. J. Infect. Dis. 196(8), 1211-1220 (2007
59. Revai K, McCormick DP, Patel J, Grady JJ, Saeed K, Chonmaitree T. Effect of pneumococcal conjugate vaccine on nasopharyngeal bacterial colonization during acute otitis media. Pediatrics 117(5), 1823-1829 (2006
60. Huang SS, Platt R, Rifas-Shiman SL, Pelton SI, Goldmann D, Finkelstein JA. Post-PCV7 changes in colonizing pneumococcal serotypes in 16 Massachusetts communities, 2001 and 2004. Pediatrics 116(3), 408-413 (2005
61. Chien YW, Vidal JE, Grijalva CG Bozio C et al. Density interactions between StrePTococcus pneumoniae, Haemophilus influenzae and Staphylococcus aureus in the nasopharynx of young Peruvian children. Pediatr. Infect. Dis. J. 32(1), 72-77 (2013
62. Kwambana BA, Barer MR, Bottomley C, Adegbola RA, Antonio M. Early acquisition and high nasopharyngeal co-colonisation by StrePTococcus pneumoniae and three respiratory pathogens amongst Gambian new-borns and infants. BMC Infect. Dis. 11, 175 (2011
63. Spijkerman J, Prevaes SM, van Gils EJ et al. Long-Term effects of pneumococcal conjugate vaccine on nasopharyngeal carriage of S. pneumoniae, S. aureus, H. influenzae and M. catarrhalis. PloS One. 7(6), e39370 (2012
64. Madhi SA, Adrian P, Kuwanda L, Cutland C, Albrich WC, Klugman KP. Long-Term effect of pneumococcal conjugate vaccine on nasopharyngeal colonization by StrePTococcus pneumoniae-And associated interactions with Staphylococcus aureus and Haemophilus influenzae colonization-in HIV-infected and HIV-uninfected children. J. Infect. Dis. 196, 1662-1666 (2007
65. Zemlickova H, Urbaskova P et al. Characteristics of StrePTococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and Staphylococcus aureus isolated from the nasopharynx of healthy children attending day-care centres in the Czech Republic. Epidemiol. Infect. 134, 1179-1187 (2006
66. van Gils EJ, Hak E et al. Effect of seven-valent pneumococcal conjugate vaccine on Staphylococcus aureus colonisation in a randomised controlled trial. PLoS One 6(6), e20229 (2011
67. van Gils EJ, Veenhoven RH, Rodenburg GD, Hak E, Sanders EA. Effect of 7-valent pneumococcal conjugate vaccine on nasopharyngeal carriage with Haemophilus influenzae and Moraxella catarrhalis in a randomized controlled trial. Vaccine 29(44), 7595-7598 (2011
68. Dunne EM, Manning J, Russell FM, Robins-Browne RM, Mulholland EK, Satzke C. Effect of pneumococcal vaccination on nasopharyngeal carriage of StrePTococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and Staphylococcus aureus in Fijian children. J. Clin. Microbiol. 50(3), 1034-1038 (2011
69. Block SL, Hedrick J, Harrison CJ et al. Community-wide vaccination with the hePTavalent pneumococcal conjugate significantly alters the microbiology of acute otitis media. Pediatr. Infect. Dis. J. 23(9), 829-833 (2004
70. Wiertsema SP, Kirkham L-AS, Corscadden KJ et al. Predominance of nontypeable Haemophilus influenzae in children with otitis media following introduction of a 3 + 0 pneumococcal conjugate vaccine schedule. Vaccine 29(32), 5163-5170 (2011
71. Prymula R, Schuerman L. 10-valent pneumococcal nontypeable Haemophilus influenzae PD conjugate vaccine: Synflorix. Expert Rev. Vaccines 8(11), 1479-1500 (2009
72. Gerber JS, Coffin SE, Smathers SA, Zaoutis TE. Trends in the incidence of methicillin-resistant Staphylococcus aureus infection in childrens hospitals in the United States. Clin. Infect. Dis. 49, 65-71 (2009
73. Ray GT, Suaya JA, Baxter R. Trends and characteristics of culture-confirmed Staphylococcus aureus infections in a large U.S. integrated health care organization. J. Clin. Microbiol. 50(6), 1950-1957 (2012
74. Louie M, Louie L, Papia G, Talbot J, Lovgren M, Simor AE. Molecular analysis of the genetic variation among penicillinsuscePTible and penicillin-resistant StrePTococcus pneumoniae serotypes in Canada. J. Infect. Dis. 179(4), 892-900 (1999
75. Lovgren M, Spika JS, Talbot JA. Invasive StrePTococcus pneumoniae infections: Serotype distribution and antimicrobial resistance in Canada, 1992-1995. Can. Med. Assoc. J. 158(327), 331 (1998
76. Davidson RJ, Low DE, Canadian Bacterial Surveillance Network. A cross-Canada surveillance of antimicrobial resistance in respiratory tract pathogens. Can. J. Infect. Dis. 158, 327-331 (1999
77. Scheifele D, Halperin S, Pelletier L et al. Reduced suscePTibility to penicillin among pneumococci causing invasive infection in children-Canada, 1991 to 1998. Can. J. Infect. Dis. 12(4), 241-246 (2001
78. Zhanel GG, Palatnick L, Nichol KA. Antimicrobial resistance in respiratory tract StrePTococcus pneumoniae isolates: Results of the Canadian respiratory organism suscePTibility study, 1997 to 2002. Antimicrob. Agents Chemother. 47(6), 1867-1874 (2003
79. Karlowsky JA, Lagace-Wiens PR, Low DE, Zhanel GG. Annual macrolide prescriPTion rates and the emergence of macrolide resistance among StrePTococcus pneumoniae in Canada from 1995 to 2005. Int. J. Antimicrob. Agents 34, 375-379 (2009
80. Vanderkooi OG, Low DE, Green K, Powis JE, McGeer A Predicting antimicrobial resistance in invasive pneumococcal infections. Clin. Infect. Dis. 40, 1288-1297 (2005
81. Powis J, McGeer A, Green K et al. In vitro antimicrobial suscePTibilities of StrePTococcus pneumoniae clinical isolates obtained in Canada in 2002. Antimicrob. Agents Chemother. 48, 3305-3311 (2004
82. Pletz M, Shergill AP, McGee L, Whitney CG et al. Prevalence of first-step mutants among levofloxacin-suscePTible invasive isolates of StrePTococcus pneumoniae in the United States. Antimicrob. Agents Chemother. 50, 1561-1563 (2006
83. Rozen DE, McGee L, Levin BR, Klugman KP. Fitness costs of fluoroquinolone resistance in StrePTococcus pneumoniae. Antimicrob. Agents Chemother. 51(2), 412-416 (2007
84. Adam HJ, Schurek KN, Nichol KA et al. Molecular characterization of increasing fluoroquinolone resistance in StrePTococcus pneumoniae isolates in Canada, 1997 to 2005. Antimicrob. Agents Chemother. 51, 198-207 (2007
85. Zhanel GG, Wang X, Nichol K et al. Molecular characterisation of Canadian paediatric multidrug-resistant StrePTococcus pneumoniae from 1998-2004. Int. J. Antimicrob. Agents 28, 465-471 (2006
86. Farrell DJ, Mendes RE, Ross JE, Sader HS, Jones RN. LEADER Program results for 2009: An activity and spectrum analysis of linezolid using 6,414 clinical isolates from 56 medical centers in the United States. Antimicrob. Agents Chemother. 55(8), 3684-3690 (2011
87. Billal DS, Feng J, Leprohon P, Légaré D, Ouellette M. Whole genome analysis of linezolid resistance in StrePTococcus pneumoniae reveals resistance and compensatory mutations. BMC. Genomics. 12, 512-521 (2011
88. Mera R, Miller LA, Fritsche TR, Jones RN. Serotype replacement and multiple resistance in StrePTococcus pneumoniae after the introduction of the conjugate pneumococcal vaccine. Microb. Drug Resist. 14, 101-107 (2008
89. Proulx JF, Dery S, Jette LP et al. Pneumonia epidemic caused by a virulent strain of StrePTococcus pneumoniae serotype 1 in Nunavik, Quebec. Can. Commun. Dis. Rep. 28(16), 129-131 (2002
90. Herva E. Features of epidemiology of StrePTococccus pneumoniae (serotype 1) in the Arctic. Int. J. Circumpolar Health 65(5), 379-381 (2006
91. Ndiaye AA, De Wals P, Proulx JF, Ouakki M, Jetté L, Déry S. Impact of a mass immunization campaign to control an outbreak of severe respiratory infections in Nunavik, northern Canada. Int. J. Circumpolar Health 65(4), 297-304 (2006
92. Mehiri-Zghal E, Decousser JW, Mahjoubi W et al. Molecular epidemiology of a StrePTococcus pneumoniae serotype 1 outbreak in a Tunisian jail. Diagn. Microbiol. Infect. Dis. 66(2), 225-227 (2010
93. Gratten M, Torzillo P, Morey F, Dixon J, Erlich J, Hagger J, Henrichden J. Distribution of capsular types and antibiotic suscePTibility of invasive StrePTococcus pneumoniae isolated from aborigines in Central Australia. J. Clin. Microbiol. 34, 338-341 (1996
94. Dagan R, Gradstein S, Belmaker I et al. An outbreak StrePTococcus pneumoniae serotype 1 in a closed community in southern Israel. Clin. Infect. Dis. 30, 319-321 (2000
95. Tyrrell GJ, Lovgren M, Ibrahim Q et al. Epidemic of invasive pneumococcal disease, western Canada. Emerg. Infect. Dis. 18(5), 733-740 (2012
96. Vanderkooi OG, Church DL, MacDonald J et al. Community-based outbreaks in vulnerable populations of invasive infections caused by StrePTococcus pneumoniae serotypes 5 and 8 in Calgary, Canada. PLOS One 6(12), e28547 (2011
97. Antonio M, Hakeem I, Awine T et al. Seasonality and outbreak of a predominant StrePTococcus pneumoniae serotype 1 clone from the Gambia: Expansion of ST217 hypervirulent clonal complex in West Africa. BMC. Microbiol. 8, 198 (2008
98. Mercat A, Nguyen J, Dautzenberg B. An outbreak of pneumococcal pneumonia in two mens shelters. Chest 99(1), 147-151 (1991
99. Hennink M, Abbas Z, McDonald RR et al. StrePTococcus pneumoniae outbreak in a rural Regina community. Can. Commun. Dis. Rep. 32(16), 181-186 (2006
100. Norcross EW, Tullos NA et al. Assessment of StrePTococcus pneumoniae capsule in conjunctivitis and keratitis in vivo neuraminidase activity increases in nonencapsulated pneumococci following conjunctival infection. Curr. Eyes Res. 35(9), 787-798 (2010
101. Routledge M. Invasive pneumococcal disease (IPD) Winnipeg inner city immunization campaign. Public Health Bulletin by Winnipeg Regional Health Authority, 31 January 2011
102. Hoge CW, Reichler MR, Dominguez EA et al. An epidemic of pneumococcal disease in an overcrowded, inadequately ventilated jail. N. Engl. J. Med. 331, 643-648 (1994
103. Cherian T, Steinhoff MC, Harrison LH, Rohn D, McDougal LK, Dick J. A cluster of invasive pneumococcal disease in young children in child care. JAMA 271, 695-697 (1994
104. CDC. Outbreak of invasive pneumococcal disease-Alaska, 2003-2004. MMWR Morb. Mortal. Wkly. Rep. 54, 72-75 (2005
105. Zulz T, Wenger JD, Rudolph K et al. StrePTococcus pneumoniae serotype 12F in Alaska: Insights from molecular characterization of isolates associated with rural community outbreaks. J. Clin. Microbiol. 51(5), 1402-1407 (2013
106. Deceuninck G, De Wals P, Boulianne N, De Serres G. Effectiveness of pneumococcal conjugate vaccine using a 2+1 infant schedule in Quebec, Canada. Pediatr. Infect. Dis. J. 29(6), 546-549 (2010
107. Lee EH, Hosea S, Schulman E et al StrePTococcus pneumoniae serotype 12F outbreak in a homeless population-California, 2004; 54th Annual Epidemic Intelligence Service (EIS) Conference, 79, Abstract (2005
108. Pilishvili T, Lexau C, Farley MM et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J. Infect. Dis. 201(1), 32-41 (2010
109. Lepoutre A, Varon E, Georges S, Gutmann L, Levy-Bruhl D. Impact of infant pneumococcal vaccination on invasive pneumococcal diseases in France, 2001-2006. Euro Surveill. 13(35), 18962 (2008
110. Linden VDM, Weiß S, Falkenhorst G et al. Four years of universal pneumococcal conjugate infant vaccination in Germany: Impact on incidence of invasive pneumococcal disease and serotype distribution in children. Vaccine 30(40), 5880-5885 (2012
111. Vestrheim DF, Lovoll O, Aaberge IS et al. Effectiveness of a 2 + 1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway. Vaccine 26, 3277-3281 (2008
112. Kaplan SL, Barson WJ, Lin PL et al. Serotype 19A is the most common serotype causing invasive pneumococcal infections in children. Pediatrics 125(3), 429-436 (2010
113. Ongkasuwan J, Valdez TA, Hulten KG, Mason EO Jr, Kaplan SL. Pneumococcal mastoiditis in children and the emergence of multidrug-resistant serotype 19A isolates. Pediatrics 122(1), 34-39 (2008
114. Xu Q, Pichichero ME, Casey JR, Zeng M. Novel type of StrePTococcus pneumoniae causing multidrug-resistant acute otitis media in children. Emerg. Infect. Dis. 15(4), 547-551 (2009
115. Moore MR, Gertz RE, Woodbury RL et al. Population snapshot of emergent StrePTococcus pneumoniae serotype 19A in the United States, 2005. J. Infect. Dis. 197, 1016-1027 (2008
116. Deng XD, Mackenzie R, Arya G, Pillai DR et al. Surveillance study of StrePTococcus pneumoniae clinical isolates among Ontario children in Canada (2007-2011): Epidemiology, serotyping, genotyping and antibiotic resistance patterns. Presented at: 52nd ICAAC. San Francisco, CA, USA, 9-12 SePTember 2012 (G3-1562
117. Pelton SI, Huot HMA, Finkelstein JA et al. Emergence of 19A as virulent and multidrug resistant pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine. Pediatr. Infect. Dis. J. 26, 468-472 (2007
118. Reinerta RR, Jacobsb MR, Kaplanc SL. Pneumococcal disease caused by serotype 19A: Review of the literature and implications for future vaccine development. Vaccine 28, 4249-4259 (2010
119. Dagan R, Givon-Lavi N, Leibovitz E, Greenberg D, Porat N. Introduction and proliferation of multidrug-resistant StrePTococcus pneumoniae serotype 19A clones that cause acute otitis media in an unvaccinated population. J. Infect. Dis. 199(6), 776-785 (2009
120. Choi EH, Kim SH et al. StrePTococcus pneumoniae serotype 19A in children, South Korea. Emerg. Infect. Dis. 14(2), 275-281 (2008
121. Pillai DR, Shahinas D, Buzina A et al. Genome-wide dissection of globally emergent multi-drug resistant serotype 19A StrePTococcus pneumoniae. BMC Genomics 10, 642 (2009
122. Dagan R, Eskola J, Leclerc C, Leroy O. Reduced response to multiple vaccines sharing common protein epitopes that are administered simultaneously to infants. Infect. Immun. 66(5), 2093-2098 (1998
123. Wizemann TM, Heinrichs JH, Adamou JE et al. Use of a whole genome approach to identify vaccine molecules affording protection against StrePTococcus pneumoniae infection. Infect. Immun. 69(3), 1593-1598 (2001
124. Adamou JE, Heinrichs JH, Erwin AL et al. Identification and characterization of a novel family of pneumococcal proteins that are protective against sepsis. Infect. Immun. 69(2), 949-958 (2001
125. Knaust A, Frosch M. Genome-based vaccines. Int. J. Med. Microbiol. 294(5), 295-301 (2004
126. Moffitt KL, Malley R. Next generation pneumococcal vaccines. Curr. Opin. Immunol. 23(3), 407-413 (2011
127. Denoël P, Philipp MT, Doyle L, Martin D, Carletti G, Poolman JT. A protein-based pneumococcal vaccine protects rhesus macaques from pneumonia after experimental infection with StrePTococcus pneumoniae. Vaccine 29(33), 5495-5501 (2011
128. Ota M, Greenwood B, Alderson M et al. Design of a strePTococcus pneumoniae immunization and carriage (SPICAR) study to assess a novel pneumococcal protein-based vaccine in Gambian children. Presented at: The 8th ISPPD conference. Iguasu Falls, Brazil, 11-15 March 2012 (Poster 281
129. Scott A. Protein based pneumococcal vaccines: Why and which protein-based pneumococcal vaccines. Presented at: Proceedings of the Tenth Global Vaccine Research Forum. Geneva, Switzerland, 26-29 June 2011
130. Bose RJC, Krishnakumar D, Jaganathan KS. The next generation pneumococcal vaccine: Intranasal immunization with trimethyl chitosan encapsulated-PSAA induces mucosal as well as systemic immunity. Presented at: The 8th ISPPD conference. Iguasu Falls, Brazil, 11-15 March 2012 (Poster 255
131. Kong I, Sato A, Yuki Y et al. Nanogel-based PspA intranasal vaccine prevents invasive disease and nasal colonization by pneumococcus. Infect. Immun. 81(5), 1625-1634 (2013
132. Webster J, Theodoratou E, Nair H, Seong AC et al. An evaluation of emerging vaccines for childhood pneumococcal pneumonia. BMC. Public Health. 11(Suppl. 3), 26 (2011